Actively Recruiting
Feasibility of Wearables in Dementia Care in Rural Taiwan
Led by China Medical University Hospital · Updated on 2026-02-11
20
Participants Needed
1
Research Sites
58 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Taiwan is becoming a super-aged society, and more older adults are living with Alzheimer's disease. Many people with Alzheimer's experience behavioral and psychological symptoms, such as agitation, sleep problems, or mood changes. These symptoms often lower their quality of life and increase stress for their family caregivers. This study will test two wearable devices in people with Alzheimer's and their caregivers. One device, called Geneactiv, is a wristwatch that tracks daily activity and sleep. The other device, called Re-Timer, is a light therapy eyewear that may help improve sleep and mood. Researchers will look at how easy the devices are to use, whether participants are willing to wear them for several weeks, and whether the light therapy helps reduce sleep problems or caregiver stress. The study will also compare information from questionnaires with information collected by the devices. The results may help researchers design future studies using wearable tools to better support people living with dementia and their caregivers.
CONDITIONS
Official Title
Feasibility of Wearables in Dementia Care in Rural Taiwan
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of probable Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease based on established criteria
- Presence of at least one prominent behavioral or psychological symptom of dementia such as depression, agitation, apathy, or nighttime sleep disturbance
- Symptoms defined as NPI single-item score ≥ 4, or NPI-Q severity score ≥ 2, or PSQI total score ≥ 5 if sleep disturbance is the main symptom
- Stable living arrangement or care environment for at least two weeks before enrollment
- Stable dosage and frequency of any pharmacological or non-pharmacological treatments for behavioral symptoms for at least two weeks before participation
- Able and willing to provide informed consent; if lacking decision-making capacity, consent from a legally authorized representative
- Adult primary caregiver of the enrolled participant
- Stable dosage and frequency of any caregiver stress treatments for at least two weeks before enrollment
- Willing and able to provide informed consent
You will not qualify if you...
- Any medical condition that may increase risk during participation, including retinal disease or use of photosensitizing medications
- Recent ocular surgery within 4 weeks or photosensitivity disorders such as epilepsy
- Unstable physical or mental conditions deemed unsuitable by investigators, such as acute delirium or active respiratory infection including COVID-19
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China Medical University Beigang Hospital
Beigang, Yunlin, Taiwan, 651
Actively Recruiting
Research Team
D
Dr Ta-Wei Guu Consultant psychiatrist, MD, PhD
CONTACT
Y
Yueh-Heng Chiang, RN, MS.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here